Glypican-3: a novel serum and histochemical marker fo

Gastroenterology

125, 89-97

DOI: 10.1016/s0016-5085(03)00689-9

Citation Report

#	Article	IF	Citations
1	Tumors of the digestive system. , 2000, , 133-182.		0
2	Hepatobiliary system and pancreas. , 2000, , 90-126.		2
3	Improvement of Liver Cancer Detection with Simultaneous Assessment of Circulating Levels of Free Alpha-Fetoprotein (AFP) and Afp-Igm Complexes. International Journal of Biological Markers, 2004, 19, 155-159.	1.8	46
4	Identification of Glypican-3 as a Novel Tumor Marker for Melanoma. Clinical Cancer Research, 2004, 10, 6612-6621.	7.0	171
5	Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cellâ€"Mediated Tumor Rejection without Autoimmune Reactions in Mice. Clinical Cancer Research, 2004, 10, 8630-8640.	7.0	87
6	The comparative study on ultrastructure and immunohistochemistry in AFP negative and positive hepatocellular carcinoma. Journal of Huazhong University of Science and Technology [Medical Sciences], 2004, 24, 547-549.	1.0	4
8	Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: Genes involved in tumor progression. Liver Transplantation, 2004, 10, 607-620.	2.4	26
9	Glypican-3 and Alphafetoprotein as Diagnostic Tests for Hepatocellular Carcinoma. Molecular Diagnosis and Therapy, 2004, 8, 207-212.	1.1	81
10	Newer markers for hepatocellular carcinoma. Gastroenterology, 2004, 127, S113-S119.	1.3	173
11	Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma. Cancer Research, 2004, 64, 2418-2423.	0.9	269
12	The role of the immune system in the control of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2004, 16, 1257-1260.	1.6	30
13	Hepatobiliary pathology. Current Opinion in Gastroenterology, 2004, 20, 188-197.	2.3	0
14	Hepatocellular Carcinoma. Cancer Journal (Sudbury, Mass), 2004, 10, 67-73.	2.0	12
15	Detection and Clinical Significance of Bone Marrow Micrometastases in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Transplantation, 2005, 80, 88-94.	1.0	13
16	New serological markers for hepatocellular carcinoma. Hepatology Research, 2005, 33, 195-197.	3.4	2
17	Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver International, 2005, 25, 962-966.	3.9	51
18	Hepatitis B surface antigenaemia and alpha-foetoprotein detection from dried blood spots: applications to field-based studies and to clinical care in hepatitis B virus endemic areas. Journal of Viral Hepatitis, 2005, 12, 642-647.	2.0	32
19	An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene, 2005, 24, 3737-3747.	5.9	122

#	Article	IF	Citations
20	Cell-surface co-receptors: emerging roles in signaling and human disease. Trends in Biochemical Sciences, 2005, 30, 611-621.	7.5	68
21	Diagnosis of small hepatocellular carcinoma. Hepatology, 2005, 42, 14-16.	7.3	85
22	Management of hepatocellular carcinoma. Hepatology, 2005, 42, 1208-1236.	7.3	5,426
23	Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer, 2005, 103, 2558-2565.	4.1	118
24	Serological markers of liver cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 91-99.	2.4	118
25	Screening for hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 101-118.	2.4	31
26	Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling. Cancer Research, 2005, 65, 6245-6254.	0.9	422
28	The Loss of Glypican-3 Induces Alterations in Wnt Signaling. Journal of Biological Chemistry, 2005, 280, 2116-2125.	3.4	191
29	How to Predict HCC Development in Patients with Chronic B Viral Liver Disease?. Intervirology, 2005, 48, 23-28.	2.8	49
30	Processing by Convertases Is Not Required for Glypican-3-induced Stimulation of Hepatocellular Carcinoma Growth. Journal of Biological Chemistry, 2005, 280, 41201-41206.	3.4	47
31	The progression of hepatitis Bâ€“ and Câ€“infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Medical Clinics of North America, 2005, 89, 345-369.	2.5	9
32	Screening Tests for Hepatocellular Carcinoma. Clinics in Liver Disease, 2005, 9, 235-251.	2.1	74
33	Liver Biopsy in the Diagnosis of Hepatocellular Carcinoma. Clinics in Liver Disease, 2005, 9, 281-285.	2.1	18
34	Usefulness of the Novel Oncofetal Antigen Glypican-3 for Diagnosis of Hepatocellular Carcinoma and Melanoma. BioDrugs, 2005, 19, 71-77.	4.6	59
36	Glypican-3 modulates inhibitory Bmp2-Smad signaling to control renal development in vivo. Mechanisms of Development, 2005, 122, 928-938.	1.7	56
37	The Progression of Hepatitis Bâ€“ and Câ€“Infections to Chronic Liver Disease and Hepatocellular Carcinoma: Presentation, Diagnosis, Screening, Prevention, and Treatment of Hepatocellular Carcinoma. Infectious Disease Clinics of North America, 2006, 20, 1-25.	5.1	9
38	Immunotherapy of hepatocellular carcinoma. Journal of Hepatology, 2006, 45, 868-878.	3.7	69
39	Prognostic Significance of Simultaneous Measurement of Three Tumor Markers in Patients With Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2006, 4, 111-117.	4.4	101

#	Article	IF	Citations
40	Cleavage of Endoplasmic Reticulum Proteins in Hepatocellular Carcinoma: Detection of Generated Fragments in Patient Sera. Gastroenterology, 2006, 130, 2010-2022.	1.3	70
41	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. Gastroenterology, 2006, 131, 1758-1767.	1.3	379
42	New frontiers in biomarkers for hepatocellular carcinoma. Digestive and Liver Disease, 2006, 38, 854-859.	0.9	34
43	Embryonic Stem Cellâ€"Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10. Cancer Research, 2006, 66, 2414-2422.	0.9	68
44	Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Human Pathology, 2006, 37, 1435-1441.	2.0	208
45	Comparative analysis of expression profiling of early-stage carcinogenesis using nodule-in-nodule-type hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2006, 18, 239-247.	1.6	20
46	Glypican 3: A Novel Marker in Testicular Germ Cell Tumors. American Journal of Surgical Pathology, 2006, 30, 1570-1575.	3.7	174
47	Lectin-reactive Î±-Fetoprotein in Patients with Tyrosinemia Type I and Hepatocellular Carcinoma. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, 77-82.	1.8	20
48	Liver Transplantation and Recurrent Hepatocellular Carcinoma: Predictive Value of Nodule Size in a Retrospective and Explant Study. Transplantation, 2006, 81, 1532-1541.	1.0	70
49	Glypican-3 Expression Distinguishes Small Hepatocellular Carcinomas From Cirrhosis, Dysplastic Nodules, and Focal Nodular Hyperplasia-like Nodules. American Journal of Surgical Pathology, 2006, 30, 1405-1411.	3.7	258
50	Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for ?-fetoprotein-producing gastric carcinoma. Histopathology, 2006, 49, 479-486.	2.9	65
51	The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Laboratory Investigation, 2006, 86, 1272-1284.	3.7	92
52	New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene, 2006, 25, 3848-3856.	5.9	143
53	Mallory body forming cells express the preneoplastic hepatocyte phenotype. Experimental and Molecular Pathology, 2006, 80, 109-118.	2.1	24
55	Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology, 2006, 44, 1012-1024.	7.3	319
56	Increased expression of glycosyl-phosphatidylinositol anchor attachment protein 1 (GPAA1) is associated with gene amplification in hepatocellular carcinoma. International Journal of Cancer, 2006, 119, 1330-1337.	5.1	39
57	Molecular Diagnostic Approach to Liver Tissue as an Ancillary Tool for Liver Histopathology. Seminars in Liver Disease, 2006, 26, 328-336.	3.6	4
58	Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma. Clinical Cancer Research, 2006, 12, 2689-2697.	7.0	161

#	Article	IF	Citations
59	Sprouty 2, an Inhibitor of Mitogen-Activated Protein Kinase Signaling, Is Down-Regulated in Hepatocellular Carcinoma. Cancer Research, 2006, 66, 2048-2058.	0.9	146
60	Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Experimental and Molecular Medicine, 2007, 39, 641-652.	7.7	43
61	High-Frequency Wireless and Electrodeless Quartz Crystal Microbalance Developed as Immunosensor. Japanese Journal of Applied Physics, 2007, 46, 4693.	1.5	15
62	Immunohistochemical Study of Glypican 3 in Thyroid Cancer. Oncology, 2007, 73, 389-394.	1.9	30
63	Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomarkers in Medicine, 2007, 1, 273-284.	1.4	19
64	Role for Amplification and Expression of Glypican-5 in Rhabdomyosarcoma. Cancer Research, 2007, 67, 57-65.	0.9	94
65	Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma. Clinical Cancer Research, 2007, 13, 1133-1139.	7.0	189
66	Tumors of the Liver. , 2007, , 943-974.		7
67	Surveillance for Hepatocellular Carcinoma and Early Diagnosis. Clinics in Liver Disease, 2007, 11, 817-837.	2.1	22
69	Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. Journal of Translational Medicine, 2007, 5, 3.	4.4	67
71	Identification of overexpressed genes in hepatocellular carcinoma, with special reference toubiquitin-conjugating enzyme E2Cgene expression. International Journal of Cancer, 2007, 121, 33-38.	5.1	98
72	Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology, 2007, 45, 725-734.	7.3	379
73	Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology, 2007, 45, 948-956.	7.3	48
74	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology, 2007, 45, 938-947.	7.3	632
75	Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology, 2007, 46, 740-748.	7.3	554
76	Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer, 2007, 109, 915-923.	4.1	124
77	Glypican-3 immunocytochemistry in liver fine-needle aspirates. Cancer, 2007, 111, 316-322.	4.1	105
78	A concise review of serum markers for hepatocellular cancer. Cancer Detection and Prevention, 2007, 31, 35-44.	2.1	91

#	Article	IF	Citations
79	Glypican-3: From the mutations of Simpsonâ€“Golabiâ€“Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Experimental and Molecular Pathology, 2007, 82, 184-189.	2.1	48
80	Hepatocellular dysplastic nodules. Hepatology Research, 2007, 37, S125-S134.	3.4	35
81	Screening of hepatocellular cancer: Japanese strategy. Hepatology Research, 2007, 37, S142-S145.	3.4	1
82	Screening for hepatocellular carcinoma. Hepatology Research, 2007, 37, S152-65.	3.4	16
83	Proteomics in discovery of hepatocellular carcinoma biomarkers. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2007, 19, 159-164.	2.2	0
84	Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clinical and Experimental Metastasis, 2008, 25, 149-159.	3.3	109
85	Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology, 2008, 48, 519-530.	7.3	77
86	Biology of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2008, 15, 962-971.	1.5	154
87	Î±-Fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. Expert Opinion on Biological Therapy, 2008, 8, 325-336.	3.1	18
88	Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Modern Pathology, 2008, 21, 626-631.	5.5	62
89	Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Modern Pathology, 2008, 21, 817-825.	5.5	97
90	Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Modern Pathology, 2008, 21, 1011-1018.	5.5	181
91	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: A case cohort study. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1259-1266.	2.8	32
92	Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by Î²â€catenin/TCF. Cancer Science, 2008, 99, 1139-1146.	3.9	47
93	Molecular background of Î±â€fetoprotein in liver cancer cells as revealed by global RNA expression analysis. Cancer Science, 2008, 99, 2402-2409.	3.9	30
94	AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer, 2008, 8, 200.	2.6	109
95	Glypicans. Genome Biology, 2008, 9, 224.	9.6	478
96	Antiâ€“Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer. Cancer Research, 2008, 68, 9832-9838.	0.9	152

#	Article	IF	Citations
97	Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Human Pathology, 2008, 39, 209-212.	2.0	79
98	Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Human Pathology, 2008, 39, 224-230.	2.0	88
99	Novel advancements in the management of hepatocellular carcinoma in 2008. Journal of Hepatology, 2008, 48, S20-S37.	3.7	739
100	Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data. European Journal of Cancer, 2008, 44, 885-897.	2.8	40
101	Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies. International Journal of Infectious Diseases, 2008, 12, e71-e76.	3.3	34
102	Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectinâ€3 knockout mice. Hepatology Research, 2008, 38, 1241-1251.	3.4	30
103	Molecular Targeting in Hepatocellular Carcinoma. , 2008, , 165-210.		1
104	Recent Advances in Tumor Markers of Human Hepatocellular Carcinoma. Intervirology, 2008, 51, 34-41.	2.8	20
105	Candidate Molecular Markers for Histological Diagnosis of Early Hepatocellular Carcinoma. Intervirology, 2008, 51, 42-45.	2.8	52
106	Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface. Biochemical Journal, 2008, 410, 503-511.	3.7	158
107	Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2008, 2, 761-784.	3.0	14
108	Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2008, 2, 425-433.	3.0	10
109	Value of Glypican 3 Immunostaining in the Diagnosis of Hepatocellular Carcinoma on Needle Biopsy. American Journal of Clinical Pathology, 2008, 130, 219-223.	0.7	71
110	EMATS FOR IMMUNOSENSORS. AIP Conference Proceedings, 2008, , .	0.4	2
111	Glypican 3 Expression in Human Nonneoplastic, Preneoplastic, and Neoplastic Tissues. American Journal of Clinical Pathology, 2008, 129, 899-906.	0.7	229
112	Detection of Glypican-3 Proteins for Hepatocellular Carcinoma Marker Using Wireless-Electrodeless Quartz-Crystal Microbalance. Japanese Journal of Applied Physics, 2008, 47, 4021-4023.	1.5	16
113	Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncology, 2008, 4, 803-814.	2.4	49
114	Oncofetal Protein Glypican-3 Distinguishes Yolk Sac Tumor From Clear Cell Carcinoma of the Ovary. American Journal of Surgical Pathology, 2008, 32, 600-607.	3.7	116

#	Article	IF	Citations
115	Tumor Markers. , 2008, , 159-182.		2
116	Application of Serial Analysis of Gene Expression in Cancer Research. Current Pharmaceutical Biotechnology, 2008, 9, 375-384.	1.6	14
117	Distinction of Hepatocellular Carcinoma From Benign Hepatic Mimickers Using Glypican-3 and CD34 Immunohistochemistry. American Journal of Surgical Pathology, 2008, 32, 433-444.	3.7	148
118	Hepatocellular Carcinoma: Management of an Increasingly Common Problem. Baylor University Medical Center Proceedings, 2008, 21, 266-280.	0.5	160
119	The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: Notes from a recent workshop. Cancer Biomarkers, 2008, 4, 19-33.	1.7	41
120	Cytokeratin 20-positive hepatocellular carcinoma. European Journal of Histochemistry, 2009, 53, .	1.5	0
121	Cytokeratin 20-positive hepatocellular carcinoma. European Journal of Histochemistry, 2009, 53, 32.	1.5	12
122	Transcriptome analysis of hepatitis B virus-associated small hepatocellular carcinoma by serial analysis of gene expression. International Journal of Oncology, 2009, 35, 129-37.	3.3	3
123	An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochimica Et Biophysica Sinica, 2009, 41, 1-15.	2.0	51
124	Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The essential role of macrophages. Cancer Biology and Therapy, 2009, 8, 930-938.	3.4	23
125	Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Review of Anticancer Therapy, 2009, 9, 1499-1510.	2.4	26
126	Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World Journal of Hepatology, 2009, 1, 48.	2.0	19
127	Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. International Journal of Oncology, 2009, 34, 649-56.	3.3	58
128	Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. Cancer Biology and Therapy, 2009, 8, 2329-2338.	3.4	58
131	A patient with the Simpsonâ€“Golabiâ€“Behmel syndrome displays a lossâ€ofâ€function point mutation in GPC3 that inhibits the attachment of this proteoglycan to the cell surface. American Journal of Medical Genetics, Part A, 2009, 149A, 552-554.	1.2	13
132	Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia. Hepatology, 2009, 49, 658-664.	7.3	722
133	Glypicanâ€3 protein expression in primary and metastatic melanoma. Cancer Cytopathology, 2009, 117, 271-278.	2.4	16
134	Utility of glypicanâ€3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fineâ€needle aspiration biopsies. Diagnostic Cytopathology, 2009, 37, 629-635.	1.0	50

#	Article	IF	Citations
135	Simultaneous determination of Î±â€fetoprotein immune complexes and Î±â€fetoprotein concentration in hepatocellular carcinoma using dualâ€label timeâ€resolved immunofluorometric assays. Journal of Clinical Laboratory Analysis, 2009, 23, 179-185.	2.1	14
136	Early HCC: diagnosis and molecular markers. Journal of Gastroenterology, 2009, 44, 108-111.	5.1	87
137	Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical application. Hepatology International, 2009, 3, 283-293.	4.2	34
138	Glypican 3â€expressing gastric carcinoma: Distinct subgroup unifying hepatoid, clearâ€cell, and Î±â€fetoproteinâ€producing gastric carcinomas. Cancer Science, 2009, 100, 626-632.	3.9	85
139	Glypicanâ€3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Science, 2009, 100, 1403-1407.	3.9	222
140	Glypican-3 expression in clear cell adenocarcinoma of the ovary. Modern Pathology, 2009, 22, 824-832.	5.5	121
141	Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBVâ€related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 55-62.	2.8	16
142	The expression profile of glypicanâ€3 and its relation to macrophage population in human hepatocellular carcinoma. Liver International, 2009, 29, 1056-1064.	3.9	28
143	Proteomic Expression Signature Distinguishes Cancerous and Nonmalignant Tissues in Hepatocellular Carcinoma. Journal of Proteome Research, 2009, 8, 1293-1303.	3.7	60
144	Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2009, 378, 279-284.	2.1	101
146	The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. Journal of Hepatology, 2009, 50, 746-754.	3.7	280
147	Disruption of Dicer1 Induces Dysregulated Fetal Gene Expression and Promotes Hepatocarcinogenesis. Gastroenterology, 2009, 136, 2304-2315.e4.	1.3	167
148	Glypican-3. Advances in Anatomic Pathology, 2009, 16, 125-129.	4.3	103
149	Agrin and CD34 Immunohistochemistry for the Discrimination of Benign Versus Malignant Hepatocellular Lesions. American Journal of Surgical Pathology, 2009, 33, 874-885.	3.7	50
150	Biomarkers for Early Detection of Liver Cancer: Focus on Clinical Evaluation. Protein and Peptide Letters, 2009, 16, 473-478.	0.9	8
151	Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis. Oncology Reports, 2009, 22, 149-54.	2.6	8
152	Diagnosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2009, 15, 1301.	3.3	140
153	Frequent Expression of Glypican-3 in Merkel Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 40-46.	1.2	22

#	Article	IF	Citations
155	Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anti-Cancer Drugs, 2010, 21, 907-916.	1.4	53
156	Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. World Journal of Gastroenterology, 2010, 16, 3521.	3.3	32
157	Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3. Acta Histochemica, 2010, 112, 240-250.	1.8	19
158	Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. Journal of Gastroenterology, 2010, 45, 451-458.	5.1	128
159	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatology International, 2010, 4, 396-405.	4.2	36
160	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatology International, 2010, 4, 439-474.	4.2	944
161	Chitosan-Alginate Scaffold Culture System for Hepatocellular Carcinoma Increases Malignancy and Drug Resistance. Pharmaceutical Research, 2010, 27, 1939-1948.	3.5	86
163	Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. International Journal of Cancer, 2010, 126, 1291-1301.	5.1	87
164	Nâ€glycan based models improve diagnostic efficacies in hepatitis B virusâ€related hepatocellular carcinoma. International Journal of Cancer, 2010, 127, 148-159.	5.1	38
165	Glypican 3 binds to GLUT1 and decreases glucose transport activity in hepatocellular carcinoma cells. Journal of Cellular Biochemistry, 2010, 111, 1252-1259.	2.6	11
166	Fibrolamellar hepatocellular carcinoma. Diagnostic Histopathology, 2010, 16, 388-396.	0.4	1
167	Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clinical Biochemistry, 2010, 43, 1003-1008.	1.9	33
168	The loss of phenol sulfotransferase 1 in hepatocellular carcinogenesis. Proteomics, 2010, 10, 266-276.	2.2	15
169	Cell-mediated immune responses to Î±-fetoprotein and other antigens in hepatocellular carcinoma. Liver International, 2010, 30, 521-526.	3.9	22
170	Glypican 3 has a higher sensitivity than alphaâ€fetoprotein for testicular and ovarian yolk sac tumour: immunohistochemical investigation with analysis of histological growth patterns. Histopathology, 2010, 56, 750-757.	2.9	84
171	Diagnostic role of serum glypicanâ€3 in differentiating hepatocellular carcinoma from nonâ€malignant chronic liver disease and other liver cancers. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 129-137.	2.8	99
172	The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 439-452.	2.8	98
173	Involvement of Aberrant Glycosylation in Thyroid Cancer. Journal of Oncology, 2010, 2010, 1-7.	1.3	34

#	Article	IF	Citations
174	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. Clinical Chemistry, 2010, 56, e1-e48.	3.2	184
175	Molecular Diagnosis of Multistage Hepatocarcinogenesis. Japanese Journal of Clinical Oncology, 2010, 40, 891-896.	1.3	35
176	Fibrolamellar Hepatocellular Carcinoma: An Immunohistochemical Comparison With Conventional Hepatocellular Carcinoma. International Journal of Surgical Pathology, 2010, 18, 313-318.	0.8	48
177	Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Modern Pathology, 2010, 23, 1180-1190.	5.5	117
179	Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis. Seminars in Liver Disease, 2010, 30, 003-016.	3.6	339
180	Molecular Signature of Early Hepatocellular Carcinoma. Oncology, 2010, 78, 36-39.	1.9	15
182	Pathology of Early Hepatocellular Carcinoma: Conventional and Molecular Diagnosis. Seminars in Liver Disease, 2010, 30, 017-025.	3.6	151
183	An Overview of Biomarkers and Molecular Signatures in HCC. Cancers, 2010, 2, 809-823.	3.7	29
184	Expression of glypican 3 in placental site trophoblastic tumor. Diagnostic Pathology, 2010, 5, 64.	2.0	25
185	Hepatocellular Carcinoma: Diagnosis, staging, and treatment strategy. Radiologia, 2010, 52, 385-398.	0.5	7
186	Genome-Wide Association Analysis in Primary Sclerosing Cholangitis. Gastroenterology, 2010, 138, 1102-1111.	1.3	325
187	Macrophage migration inhibitory factor plays a pivotal role in hepatocellular carcinoma and may be a noninvasive imaging target. Medical Hypotheses, 2010, 75, 530-532.	1.5	5
189	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. Annual Review of Medicine, 2010, 61, 317-328.	12.2	229
190	Î³-Glutamyl transpeptidase is a heavily N-glycosylated heterodimer in HepG2 cells. Archives of Biochemistry and Biophysics, 2010, 504, 177-181.	3.0	13
191	Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypicanâ€3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatology Research, 2010, 40, 477-485.	3.4	54
192	Cell-Extracellular Matrix Interactions in Cancer. , 2010, , .		22
193	Generation of functional CD8+ T Cells by human dendritic cells expressing glypican-3 epitopes. Journal of Experimental and Clinical Cancer Research, 2010, 29, 48.	8.6	18
194	Evaluation of macrophage migration inhibitory factor as an imaging marker for hepatocellular carcinoma in murine models. Scandinavian Journal of Gastroenterology, 2011, 46, 720-726.	1.5	5

#	Article	IF	Citations
195	Global Gene Profiling of Spontaneous Hepatocellular Carcinoma in B6C3F1 Mice. Toxicologic Pathology, 2011, 39, 678-699.	1.8	35
196	Advances in Liver Cancer Antibody Therapies. BioDrugs, 2011, 25, 275-284.	4.6	46
197	Recent Advances in Cytogenetics and Molecular Biology of Adult Hepatocellular Tumors: Implications for Imaging and Management. Radiology, 2011, 258, 673-693.	7.3	68
199	Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, S21-S30.	1.5	18
200	Diagnosis of Hepatocellular Carcinoma: Role of Tumor Markers and Liver Biopsy. Clinics in Liver Disease, 2011, 15, 297-306.	2.1	37
201	Suppression of Glypican 3 Inhibits Growth of Hepatocellular Carcinoma Cells through Up-Regulation of TGF-Î²2. Neoplasia, 2011, 13, 735-IN25.	5.3	82
202	Direct tissue analysis by MALDI-TOF mass spectrometry in human hepatocellular carcinoma. Clinica Chimica Acta, 2011, 412, 230-239.	1.1	23
203	Glypican-3: A new target for cancer immunotherapy. European Journal of Cancer, 2011, 47, 333-338.	2.8	192
204	Chemiluminescence enzyme immunoassay based on magnetic nanoparticles for detection of hepatocellular carcinoma marker glypican-3. Journal of Pharmaceutical Analysis, 2011, 1, 166-174.	5.3	18
205	A lung cancer gene GPC5 could also be crucial in breast cancer. Molecular Genetics and Metabolism, 2011, 103, 104-105.	1.1	25
206	Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Current Oncology, 2011, 18, 228-240.	2.2	55
207	Fine-Needle Aspiration Biopsy of Hepatocellular Carcinoma and Related Hepatocellular Nodular Lesions in Cirrhosis: Controversies, Challenges, and Expectations. Pathology Research International, 2011, 2011, 1-17.	1.4	27
208	Diagnostic and Prognostic Molecular Markers in Hepatocellular Carcinoma. Disease Markers, 2011, 31, 181-190.	1.3	67
209	Glypican-3 Targeting of Liver Cancer Cells Using Multifunctional Nanoparticles. Molecular Imaging, 2011, 10, 7290.2010.00048.	1.4	37
210	Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 960-964.	2.8	30
211	Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis. Cytopathology, 2011, 22, 287-305.	0.7	59
212	Induction of latencyâ€associated peptide (transforming growth factorâ€Î²₁) expression on CD4⁺ T cells reduces Tollâ€like receptor 4 ligandâ€induced tumour necrosis factorâ€Î± production in a transforming growth factorâ€Î²â€dependent manner. Immunology, 2011, 133, 278-287.	4.4	9
213	Prognostic significance of circumferential cell surface immunoreactivity of glypicanâ€3 in hepatocellular carcinoma. Liver International, 2011, 31, 120-131.	3.9	51

#	Article	IF	Citations
214	Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. Journal of Cellular and Molecular Medicine, 2011, 15, 1013-1031.	3.6	484
215	Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. Clinical Immunology, 2011, 139, 302-313.	3.2	18
216	Hepatocellular tumors: Immunohistochemical analyses for classification and prognostication. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2011, 23, 245-253.	2.2	23
217	Seminal vesicle metastasis after partial hepatectomy for hepatocellular carcinoma. BMC Cancer, 2011, 11, 111.	2.6	10
218	Hepatocyte proliferation and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 transgenic mice. Hepatology, 2011, 54, 620-630.	7.3	23
219	Neighbor of punc E11, a novel oncofetal marker for hepatocellular carcinoma. International Journal of Cancer, 2011, 128, 2353-2363.	5.1	15
220	Identification of a secretory protein c19orf10 activated in hepatocellular carcinoma. International Journal of Cancer, 2011, 129, 1576-1585.	5.1	19
221	Detection of Î±-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. Journal of Clinical Laboratory Analysis, 2011, 25, 113-117.	2.1	13
222	Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. Journal of Clinical Laboratory Analysis, 2011, 25, 350-353.	2.1	43
223	Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathology Research and Practice, 2011, 207, 8-14.	2.3	33
224	Intrahepatic Cholangiocarcinoma: New Insights in Pathology. Seminars in Liver Disease, 2011, 31, 049-060.	3.6	166
225	Diagnosis of Well-differentiated Hepatocellular Lesions. Advances in Anatomic Pathology, 2011, 18, 438-445.	4.3	73
226	Early Transcriptional Responses of HepG2-A16 Liver Cells to Infection by Plasmodium falciparum Sporozoites. Journal of Biological Chemistry, 2011, 286, 26396-26405.	3.4	26
227	EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut, 2011, 60, 967-976.	12.1	162
228	Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics. Clinical Chemistry and Laboratory Medicine, 2011, 49, 959-66.	2.3	19
229	Assessment of Stromal Invasion for Correct Histological Diagnosis of Early Hepatocellular Carcinoma. International Journal of Hepatology, 2011, 2011, 1-7.	1.1	12
230	GPC5 Gene and Its Related Pathways in Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 2-5.	1.1	51
232	Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas. Journal of Clinical Pathology, 2011, 64, 587-591.	2.0	18

#	Article	IF	Citations
233	An Overview of Biomarkers for the Diagnosis of Hepatocellular Carcinoma. Hepatitis Monthly, 2012, 12, e6122.	0.2	26
234	Phase I Trial of a Glypican-3â€"Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival. Clinical Cancer Research, 2012, 18, 3686-3696.	7.0	246
235	Hepatitis C virus and hepatocarcinogenesis. Clinical and Molecular Hepatology, 2012, 18, 347.	8.9	81
236	Hepatocellular Carcinoma: Important Biomarkers and their Significance in Molecular Diagnostics and Therapy. Current Medicinal Chemistry, 2012, 19, 3722-3729.	2.4	22
237	High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. MAbs, 2012, 4, 592-599.	5.2	69
238	Cellular Immune Responses to Hepatocellular Carcinoma: Lessons for Immunotherapy. Digestive Diseases, 2012, 30, 483-491.	1.9	36
239	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 61, 1481-1487.	12.1	154
240	LRP1 mediates the Shh-induced endocytosis of the GPC3-Shh complex. Journal of Cell Science, 2012, 125, 3380-9.	2.0	43
241	Monoclonal Antibody Against Glypican-3. Hybridoma, 2012, 31, 475-475.	0.4	0
242	A Functional Insertion/Deletion Polymorphism in the Proximal Promoter ofCD3GIs Associated with Susceptibility for Hepatocellular Carcinoma in Chinese Population. DNA and Cell Biology, 2012, 31, 1480-1485.	1.9	6
243	The Application of a Three-Step Serum Proteome Analysis for the Discovery and Identification of Novel Biomarkers of Hepatocellular Carcinoma. International Journal of Proteomics, 2012, 2012, 1-12.	2.0	17
244	Biomarkers for Hepatocellular Carcinoma. International Journal of Hepatology, 2012, 2012, 1-7.	1.1	97
245	Immunohistochemical Detection of Glypican-5 in Paraffin-embedded Material. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 189-195.	1.2	2
246	Hepatocarcinoma. Medicine, 2012, 11, 693-703.	0.0	0
247	Management of HCC. Journal of Hepatology, 2012, 56, S75-S87.	3.7	509
248	Hepatocellualar Carcinoma Serum Markers. Seminars in Oncology, 2012, 39, 410-433.	2.2	147
249	Preparation and Characterization of Monoclonal Antibody Against Glypican-3. Hybridoma, 2012, 31, 455-461.	0.4	8
251	EASLâ€"EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 908-943.	3.7	5,214

#	Article	IF	Citations
252	Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 2012, 419, 656-661.	2.1	29
253	EASLâ€"EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. European Journal of Cancer, 2012, 48, 599-641.	2.8	406
254	Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library. BMC Biotechnology, 2012, 12, 23.	3.3	6
255	Surveillance for Hepatocellular Carcinoma. Seminars in Oncology, 2012, 39, 384-398.	2.2	52
256	Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma?. European Journal of Internal Medicine, 2012, 23, e157-e161.	2.2	10
257	Role of glypican-3 in the early diagnosis of hepatocellular carcinoma among Egyptian patients. Journal of Genetic Engineering and Biotechnology, 2012, 10, 73-79.	3.3	8
258	New Serum Markers of Hepatocellular Carcinoma. Seminars in Oncology, 2012, 39, 434-439.	2.2	78
259	Chronic Hepatitis C Virus. , 2012, , .		3
261	Recent Advances in the Immunohistochemistry- Aided Differential Diagnosis of Benign Versus Malignant Hepatocellular Lesions. , 2012, , .		0
263	Biomarkers for hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2012, 5, 177-182.	0.8	6
264	Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: A tissue microarray-based study. Acta Histochemica, 2012, 114, 547-552.	1.8	49
265	Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology, 2012, 82, 116-140.	4.4	73
266	Hepatocellular carcinoma: diagnostics and screening. Journal of Evaluation in Clinical Practice, 2012, 18, 335-342.	1.8	46
267	Hepatoid carcinoma of the pancreas penetrating into the gastric cavity: A case report and literature review. Pathology International, 2012, 62, 485-490.	1.3	31
268	Antithetic roles of proteoglycans in cancer. Cellular and Molecular Life Sciences, 2012, 69, 553-579.	5.4	33
269	Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Molecular Biology Reports, 2012, 39, 351-357.	2.3	53
270	A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values. BMC Cancer, 2013, 13, 161.	2.6	23
271	A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1417-1424.	2.5	50

#	Article	IF	Citations
272	Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery, 2013, 154, 536-544.	1.9	76
273	A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability. Annals of Surgical Oncology, 2013, 20, 325-339.	1.5	486
274	Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions. Annals of Diagnostic Pathology, 2013, 17, 490-493.	1.3	17
275	Induction of CD152 (CTLA-4) and LAP (TGF-Î²1) in human Foxp3â^' CD4+ CD25â^' T cells modulates TLR-4 induced TNF-Î± production. Immunobiology, 2013, 218, 427-434.	1.9	3
276	Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Human Pathology, 2013, 44, 542-550.	2.0	48
277	Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis. Science China Life Sciences, 2013, 56, 234-239.	4.9	15
278	A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Medical Molecular Morphology, 2013, 46, 141-152.	1.0	277
279	Glypicanâ€3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS Journal, 2013, 280, 2471-2476.	4.7	142
280	Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clinica Chimica Acta, 2013, 423, 105-111.	1.1	42
281	Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods. European Journal of Medical Research, 2013, 18, 35.	2.2	11
282	Hepatocellular Carcinoma from an Immunologic Perspective. Clinical Cancer Research, 2013, 19, 6678-6685.	7.0	89
283	Swarm chondrosarcoma: a continued resource for chondroblastic-like extracellular matrix and chondrosarcoma biology research. Connective Tissue Research, 2013, 54, 252-259.	2.3	12
284	Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination. Human Vaccines and Immunotherapeutics, 2013, 9, 1228-1233.	3.3	30
285	Molecular Imaging of Hepatocellular Carcinoma Xenografts with Epidermal Growth Factor Receptor Targeted Affibody Probes. BioMed Research International, 2013, 2013, 1-11.	1.9	21
286	Immunohistochemical Expression of Glypican-3 in Pediatric Tumors: An Analysis of 414 Cases. Pediatric and Developmental Pathology, 2013, 16, 272-277.	1.0	35
287	Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1083-91.	7.1	156
288	Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 3944-3954.	7.0	108
289	Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World Journal of Gastroenterology, 2013, 19, 6744.	3.3	50

#	Article	IF	Citations
290	Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1343-1352.	2.5	65
291	Diagnostic Value of Immunohistochemical Staining of GP73, GPC3, DCP, CD34, CD31, and Reticulin Staining in Hepatocellular Carcinoma. Journal of Histochemistry and Cytochemistry, 2013, 61, 639-648.	2.5	33
292	First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 920-928.	7.0	160
293	Association of cyclin D and estrogen receptor Î±36 with hepatocellular adenomas of female mice under chronic endoplasmic reticulum stress. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 576-583.	2.8	11
294	Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide. International Journal of Oncology, 2013, 43, 1019-1026.	3.3	22
295	Multifocal Hepatic Neoplasia in 3 Children With APC Gene Mutation. American Journal of Surgical Pathology, 2013, 37, 1058-1066.	3.7	26
296	Protein Biomarkers in Cancers of the Digestive Tract - a Step Towards Personalized Medicine. Current Proteomics, 2013, 10, 228-236.	0.3	2
297	Dickkopf-1: As a Diagnostic and Prognostic Serum Marker for Early Hepatocellular Carcinoma. International Journal of Biological Markers, 2013, 28, 286-297.	1.8	39
298	Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients. African Health Sciences, 2013, 13, 703-9.	0.7	31
299	Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 35.	3.7	17
300	Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World Journal of Gastroenterology, 2014, 20, 10249.	3.3	56
301	Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: A meta-analysis. World Journal of Gastroenterology, 2014, 20, 6336.	3.3	31
302	Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 6418-6428.	7.0	233
303	Expression of Aldo-Keto Reductase Family 1 Member B10 in the Early Stages of Human Hepatocarcinogenesis. International Journal of Molecular Sciences, 2014, 15, 6556-6568.	4.1	34
304	Can Serum Glypican-3 Be a Biomarker for Effective Diagnosis of Hepatocellular Carcinoma? A Meta-Analysis of the Literature. Disease Markers, 2014, 2014, 1-11.	1.3	21
305	Granulin-epithelin precursor interacts with heparan sulfate on liver cancer cells. Carcinogenesis, 2014, 35, 2485-2494.	2.8	14
306	Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis. Archives of Medical Research, 2014, 45, 580-588.	3.3	60
307	<scp>G</scp>olgi protein 73, not Glypicanâ€3, may be a tumor marker complementary to Î±â€Fetoprotein for hepatocellular carcinoma diagnosis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 597-602.	2.8	42

#	Article	IF	Citations
308	Japanese phase I study of <scp>GC</scp>33, a humanized antibody against glypicanâ€3 for advanced hepatocellular carcinoma. Cancer Science, 2014, 105, 455-462.	3.9	60
309	Arginase-1 is a Novel Immunohistochemical Marker of Hepatocellular Differentiation. Advances in Anatomic Pathology, 2014, 21, 285-290.	4.3	19
310	Discovery and Diagnostic Value of a Novel Oncofetal Protein. Advances in Anatomic Pathology, 2014, 21, 450-460.	4.3	20
311	GPC3 reduces cell proliferation in renal carcinoma cell lines. BMC Cancer, 2014, 14, 631.	2.6	31
312	Immunotherapy of hepatocellular carcinoma. Hepatic Oncology, 2014, 1, 433-446.	4.2	5
313	The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. Journal of Surgical Research, 2014, 187, 377-385.	1.6	42
314	Imaging of hepatocellular carcinoma patient-derived xenografts using 89Zr-labeled anti-glypican-3 monoclonal antibody. Biomaterials, 2014, 35, 6964-6971.	11.4	39
315	Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. Journal of Gastroenterology, 2014, 49, 117-125.	5.1	51
316	Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis. Alexandria Journal of Medicine, 2014, 50, 221-226.	0.6	18
317	Glypican-3 binds to frizzled and plays a direct role in the stimulation of canonical Wnt signaling. Journal of Cell Science, 2014, 127, 1565-75.	2.0	146
318	Mesenchymal stem cells, neural lineage potential, heparan sulfate proteoglycans and the matrix. Developmental Biology, 2014, 388, 1-10.	2.0	49
319	Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis. Clinical Biochemistry, 2014, 47, 196-200.	1.9	20
320	Glypicanâ€3 antibodies: A new therapeutic target for liver cancer. FEBS Letters, 2014, 588, 377-382.	2.8	88
321	Assessing compound carcinogenicityin vitrousing connectivity mapping. Carcinogenesis, 2014, 35, 201-207.	2.8	38
322	Hepatocellular carcinoma tumour markers: Current role and expectations. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 843-853.	2.4	89
323	Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infection, Genetics and Evolution, 2014, 26, 327-339.	2.3	24
324	Glypican-3-expressing Gastric Metastasis of Hepatocellular Carcinoma via Curative Subtotal Gastrectomy: A Case Report. Journal of Gastrointestinal Cancer, 2014, 45, 166-169.	1.3	2
325	Neonatal streptozotocin treatment causes type 1 diabetes and subsequent hepatocellular carcinoma in DIAR mice fed a normal diet. Hepatology International, 2014, 8, 415-424.	4.2	6

#	Article	IF	Citations
326	Impaired autophagy response in human hepatocellular carcinoma. Experimental and Molecular Pathology, 2014, 96, 149-154.	2.1	74
328	The Changing Landscape of Hepatocellular Carcinoma. American Journal of Pathology, 2014, 184, 574-583.	3.8	82
329	Glypican-3â€“Targeted ⁸⁹Zr PET Imaging of Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2014, 55, 799-804.	5.0	56
330	Comparing Prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins Glypican-3, Alpha feto protein and Carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients. Journal of the Egyptian National Cancer Institute, 2014, 26, 79-85.	1.5	22
331	Expression of neighbor of Punc E11 in hepatocarcinogenesis induced by diethylnitrosamine. Oncology Reports, 2014, 32, 1043-1049.	2.6	7
332	Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells. Molecular Medicine Reports, 2014, 10, 3177-3184.	2.4	33
333	GPC3 expression in mouse ovarian cancer induces GPC3-specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth. Oncology Reports, 2014, 32, 913-921.	2.6	13
334	Fine Needle Aspiration Biopsy (FNAB) in the Diagnosis of Hepatocellular Carcinoma: A Review. Romanian Journal of Internal Medicine, 2015, 53, 209-217.	0.4	4
335	Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. International Journal of Oncology, 2015, 46, 28-36.	3.3	69
336	Mucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways. Molecular Medicine Reports, 2015, 12, 6782-6788.	2.4	6
338	High preoperative levels of serum glypicanâ€3 containing <scp>N</scp>â€terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. International Journal of Cancer, 2015, 137, 1643-1651.	5.1	34
339	A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	2.5	3
340	Biomarkers for the early diagnosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 10573.	3.3	377
341	Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget, 2015, 6, 9551-9563.	1.8	48
342	Ancillary studies. , 0, , 250-272.		0
343	Aptamer-based Sandwich Assay and its Clinical Outlooks for Detecting Lipocalin-2 in Hepatocellular Carcinoma (HCC). Scientific Reports, 2015, 5, 10897.	3.3	58
344	T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells InÂVitro and inÂMice. Gastroenterology, 2015, 149, 1042-1052.	1.3	96
345	Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepatic Medicine: Evidence and Research, 2015, 7, 1.	2.5	25

#	Article	IF	Citations
346	Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalinâ€fixed tumor vaccine, with special reference to glypicanâ€3. Clinical Case Reports (discontinued), 2015, 3, 444-447.	0.5	10
347	Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. International Journal of Oncology, 2015, 46, 1275-1285.	3.3	52
348	An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. International Immunopharmacology, 2015, 24, 335-345.	3.8	73
349	A novel ultrasensitive electrochemical immunosensor based on carboxy-endcapped conductive polypyrrole for the detection of gypican-3 in human serum. Analytical Methods, 2015, 7, 1745-1750.	2.7	13
350	Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers. Carcinogenesis, 2015, 36, 232-242.	2.8	32
351	Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer, 2015, 51, 327-339.	2.8	63
352	Immunostaining in Lung Cancer for the Clinician. Commonly Used Markers for Differentiating Primary and Metastatic Pulmonary Tumors. Annals of the American Thoracic Society, 2015, 12, 429-435.	3.2	8
353	Elevated Alpha-Fetoprotein. Clinics in Liver Disease, 2015, 19, 309-323.	2.1	118
354	Prognostic impact of surgery and radiofrequency ablation on single nodular HCC â©½5 cm: Cohort study based on serum HCC markers. Journal of Hepatology, 2015, 63, 1352-1359.	3.7	57
355	Glypican-3 Targeted Human Heavy Chain Antibody as a Drug Carrier for Hepatocellular Carcinoma Therapy. Molecular Pharmaceutics, 2015, 12, 2151-2157.	4.6	59
356	Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer, 2015, 4, 126-136.	7.7	125
357	Anatomic Pathology of Hepatocellular Carcinoma. Clinics in Liver Disease, 2015, 19, 239-259.	2.1	22
358	CK19 is a sensitive marker for yolk sac tumours of the testis. Diagnostic Pathology, 2015, 10, 7.	2.0	10
359	Immunohistochemistry as a surrogate for molecular diagnosis in hepatic tumours. Diagnostic Histopathology, 2015, 21, 108-115.	0.4	1
360	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. Expert Opinion on Therapeutic Targets, 2015, 19, 973-983.	3.4	9
361	Processing by Convertases Is Required for Glypican-3-induced Inhibition of Hedgehog Signaling. Journal of Biological Chemistry, 2015, 290, 7576-7585.	3.4	28
362	Glypican 3 Expression in Pediatric Malignant Solid Tumors. European Journal of Pediatric Surgery, 2015, 25, 138-144.	1.3	28
363	Detection of liver cancer cells by using ELISA and coupling of anti-glypican 3 antibody and magnetite nanoparticles. Geosystem Engineering, 2015, 18, 219-225.	1.4	7

#	Article	IF	Citations
364	CAGE profiling of ncRNAs in hepatocellular carcinoma reveals widespread activation of retroviral LTR promoters in virus-induced tumors. Genome Research, 2015, 25, 1812-1824.	5.5	49
365	Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine, 2015, 10, 1139-1147.	3.3	53
366	Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma. Histopathology, 2015, 66, 598-602.	2.9	36
367	Development of a Clinical Chemiluminescent Immunoassay for Serum GPC3 and Simultaneous Measurements Alone With AFP and CK19 in Diagnosis of Hepatocellular Carcinoma. Journal of Clinical Laboratory Analysis, 2015, 29, 85-93.	2.1	42
368	Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 275.	3.3	87
369	Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and Cancer. F1000Research, 2016, 5, 1541.	1.6	38
370	Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection. Oncotarget, 2016, 7, 72276-72289.	1.8	25
371	Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 8271.	3.3	33
372	Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. International Journal of Nanomedicine, 2016, Volume 11, 5645-5669.	6.7	108
373	Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 262.	3.3	96
374	Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins, 2016, 8, 274.	3.4	19
375	GPC-3 in hepatocellular carcinoma: current perspectives. Journal of Hepatocellular Carcinoma, 2016, Volume 3, 63-67.	3.7	62
376	Antiâ€Glypican 3, a Novel Ancillary Maker in the Histological Assessment of Hirschsprung's Disease. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 692-697.	1.8	2
377	BSEP and MDR3. American Journal of Surgical Pathology, 2016, 40, 689-696.	3.7	35
378	GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma. Tumor Biology, 2016, 37, 12571-12577.	1.8	19
379	Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. International Journal of Cancer, 2016, 139, 1764-1775.	5.1	169
380	Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer, 2016, 5, 221-232.	7.7	44
381	In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft. Photoacoustics, 2016, 4, 43-54.	7.8	14

#	Article	IF	Citations
382	The application of proteomics in different aspects of hepatocellular carcinoma research. Journal of Proteomics, 2016, 145, 70-80.	2.4	20
383	Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma. Digestive Diseases, 2016, 34, 429-437.	1.9	21
384	Aptamers against Cells Overexpressing Glypicanâ€...3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory Evolution. Angewandte Chemie - International Edition, 2016, 55, 12372-12375.	13.8	78
385	Screening and surveillance for hepatocellular carcinoma: perspective of a new era?. Expert Review of Anticancer Therapy, 2016, 16, 1291-1302.	2.4	4
386	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Medicina ClÃnica (English Edition), 2016, 146, 511.e1-511.e22.	0.2	2
387	Surveillance for Hepatocellular Carcinoma. , 2016, , 339-354.		1
388	The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas. Cancer Letters, 2016, 382, 245-254.	7.2	25
389	Protein Biomarkers in the Management of Hepatocellular Carcinoma: Novel Combinatory Approaches. , 2016, , 331-338.		0
390	Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3. FEBS Journal, 2016, 283, 3739-3754.	4.7	125
391	Aptamers against Cells Overexpressing Glypicanâ€...3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory Evolution. Angewandte Chemie, 2016, 128, 12560-12563.	2.0	9
392	Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma. Scientific Reports, 2016, 6, 33878.	3.3	50
393	An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells. Journal of Biological Chemistry, 2016, 291, 24676-24687.	3.4	14
394	Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomarkers in Cancer, 2016, 8s1, BIC.S34413.	3.6	79
395	Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate. Scientific Reports, 2016, 6, 26245.	3.3	44
396	The utility of immunohistochemical expression of glypican-3 (GPC3) and enhancer of zeste homologue-2 (EZH2) protein in the diagnosis of liver nodules. Egyptian Journal of Pathology, 2016, 36, 267-275.	0.0	0
397	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2016, 65, 289-295.	3.7	89
398	A rare case of hepatocellular carcinoma metastasizing hematogenously to the rectum. International Cancer Conference Journal, 2016, 5, 168-173.	0.5	3
399	Transcriptome Analysis of WHV/c-myc Transgenic Mice Implicates Cytochrome P450 Enzyme 17A1 as a Promising Biomarker for Hepatocellular Carcinoma. Cancer Prevention Research, 2016, 9, 739-749.	1.5	7

#	Article	IF	Citations
400	Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma. Modern Pathology, 2016, 29, 283-292.	5.5	43
401	Identification of NUCKS1 as a putative oncogene and immunodiagnostic marker of hepatocellular carcinoma. Gene, 2016, 584, 47-53.	2.2	20
402	Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging. Bioconjugate Chemistry, 2016, 27, 831-839.	3.6	49
403	Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. OncoImmunology, 2016, 5, e1129483.	4.6	125
405	Ultrasensitive, Multiplex Raman Frequency Shift Immunoassay of Liver Cancer Biomarkers in Physiological Media. ACS Nano, 2016, 10, 871-879.	14.6	91
406	Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 853-869.	3.3	89
407	Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst, The, 2016, 141, 36-44.	3.5	60
408	Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma. Technology in Cancer Research and Treatment, 2016, 15, 780-786.	1.9	18
409	Advanced Diagnostic Techniques. , 2016, , 453-494.		11
410	Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-Î¹B translocation. International Immunopharmacology, 2017, 44, 174-182.	3.8	89
411	Diagnostic histopathology of hepatocellular carcinoma: A case-based review. Seminars in Diagnostic Pathology, 2017, 34, 126-137.	1.5	17
412	Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens. Human Pathology, 2017, 63, 1-13.	2.0	34
413	The significance of glypicanâ€3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1503-1511.	2.8	24
414	Glypican 3 as a Serum Marker for Hepatoblastoma. Scientific Reports, 2017, 7, 45932.	3.3	21
415	Human Hepatocarcinoma Cell Targeting by Glypican-3 Ligand Peptide Functionalized Silica Nanoparticles: Implications for Ultrasound Molecular Imaging. Langmuir, 2017, 33, 4490-4499.	3.5	15
416	Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3. Journal of Fluorescence, 2017, 27, 1479-1485.	2.5	20
417	Study on a new high affinity anti-glypicans-3 antibody in diagnosis of early hepatocellular carcinoma by differential pulse voltammetry. Journal of Solid State Electrochemistry, 2017, 21, 1631-1637.	2.5	11
418	Bioinformatics analysis of gene expression alterations in microRNA-122 knockout mice with hepatocellular carcinoma. Molecular Medicine Reports, 2017, 15, 3681-3689.	2.4	10

#	Article	IF	Citations
421	Glypican-3 as a Target for Immune Based Therapy in Hepatocellular Carcinoma. , 2017, , 103-119.		1
422	New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. Journal of Controlled Release, 2017, 268, 184-197.	9.9	33
423	A novel, rapid, and sensitive homogeneous sandwich detection method of Glypican-3 as a serum marker for hepatocellular carcinoma. Chemical Communications, 2017, 53, 12209-12212.	4.1	7
424	Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis. Journal of Gastrointestinal Cancer, 2017, 48, 225-237.	1.3	2
425	Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial. EBioMedicine, 2017, 24, 56-63.	6.1	80
426	Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. Scientific Reports, 2017, 7, 9608.	3.3	24
427	Hepatocellular Carcinoma: Epidemiology, Basic Principles of Treatment, and Clinical Data. , 2017, , 149-178.		0
428	Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches. Frontiers of Medicine, 2017, 11, 509-521.	3.4	19
429	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. OncoImmunology, 2017, 6, e1363139.	4.6	60
430	MXR7 facilitates liver cancer metastasis via epithelial-mesenchymal transition. Science China Life Sciences, 2017, 60, 1203-1213.	4.9	8
431	A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Molecular Therapy, 2017, 25, 2299-2308.	8.2	21
432	Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. OncoImmunology, 2017, 6, e1346764.	4.6	69
433	Cellular characteristics of keratin 19â€positive canine hepatocellular tumours explain its aggressive behaviour. Veterinary Record Open, 2017, 4, e000212.	1.0	3
435	Identification of a Glypicanâ€3â€Binding Peptide for In Vivo Nonâ€Invasive Human Hepatocellular Carcinoma Detection. Macromolecular Bioscience, 2017, 17, 1600335.	4.1	21
438	Tissue Biomarkers in Hepatocellular Tumors: Which, When, and How. Frontiers in Medicine, 2017, 4, 10.	2.6	21
439	Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma. International Journal of Biological Markers, 2017, 32, 361-369.	1.8	12
440	Biochemical and molecular evidences for the antitumor potential of Ginkgo biloba leaves extract in rodents.. Acta Biochimica Polonica, 2017, 64, 25-33.	0.5	9
441	Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 93-103.	3.7	58

#	Article	IF	Citations
442	Clinicopathological features of combined hepatocellular-cholangiocarcinoma with sarcomatous change. Medicine (United States), 2018, 97, e9640.	1.0	8
443	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 182-236.	3.7	6,153
445	Singleâ€cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology, 2018, 68, 127-140.	7.3	231
447	Biomarker Discovery and Validation in HCC Diagnosis, Prognosis, and Therapy. Molecular Pathology Library, 2018, , 95-113.	0.1	1
448	Hepatocellular carcinoma. Lancet, The, 2018, 391, 1301-1314.	13.7	3,878
449	Update on Ancillary Testing in the Evaluation of High-Grade Liver Tumors. Surgical Pathology Clinics, 2018, 11, 367-375.	1.7	8
450	Slow Off-Rate Modified Aptamer (SOMAmer) as a Novel Reagent in Immunoassay Development for Accurate Soluble Glypican-3 Quantification in Clinical Samples. Analytical Chemistry, 2018, 90, 5162-5170.	6.5	24
451	Hepatitis C Virus Mimics Effects of Glypican-3 on CD81 and Promotes Development of Hepatocellular Carcinomas via Activation of Hippo Pathway in Hepatocytes. American Journal of Pathology, 2018, 188, 1469-1477.	3.8	18
452	Polyclonal antibody production against rGPC3 and their application in diagnosis of hepatocellular carcinoma. Preparative Biochemistry and Biotechnology, 2018, 48, 435-445.	1.9	3
453	Glypicanâ€3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Medicinal Research Reviews, 2018, 38, 741-767.	10.5	226
454	Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2018, 437, 13-36.	3.1	29
455	Diagnostic Value of Glypican3, Heat Shock Protein 70 and Glutamine Synthetase in Hepatocellular Carcinoma Arising in Cirrhotic and Non-Cirrhotic Livers. Journal of Clinical and Experimental Hepatology, 2018, 8, 173-180.	0.9	15
456	Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?. Cancer Immunology, Immunotherapy, 2018, 67, 161-174.	4.2	24
457	Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity. Redox Biology, 2018, 14, 237-249.	9.0	47
458	Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 317-325.	3.3	12
459	Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget, 2018, 9, 10436-10444.	1.8	11
460	Low glucose metabolism in hepatocellular carcinoma with GPC3 expression. World Journal of Gastroenterology, 2018, 24, 494-503.	3.3	20
461	Circular RNA Hsa_Circ_0091579 Serves as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma. Cellular Physiology and Biochemistry, 2018, 51, 290-300.	1.6	38

#	Article	IF	Citations
462	Signaling network involved in the GPC3-induced inhibition of breast cancer progression: role of canonical Wnt pathway. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2399-2418.	2.5	16
463	Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2018, 19, 3070.	4.1	41
464	Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. Frontiers in Pharmacology, 2018, 9, 1118.	3.5	126
465	Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics. Chemical Reviews, 2018, 118, 9152-9232.	47.7	253
466	Novel biomarkers in hepatocellular carcinoma. Digestive and Liver Disease, 2018, 50, 1115-1123.	0.9	104
467	Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy, 2018, 10, 1077-1091.	2.0	6
468	Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Hepatobiliary and Pancreatic Diseases International, 2018, 17, 301-309.	1.3	59
469	Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials. Experimental Cell Research, 2018, 369, 1-10.	2.6	30
470	Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: a systematic review with meta-analysis. International Journal of Biological Markers, 2018, 33, 353-363.	1.8	11
471	Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma. Scientific Reports, 2018, 8, 10283.	3.3	21
472	Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2018, 18, 713-722.	3.1	6
473	I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Research, 2018, 8, 20.	2.5	17
474	A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma. International Journal of Nanomedicine, 2018, Volume 13, 4433-4443.	6.7	32
475	Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity. European Journal of Histochemistry, 2018, 62, 2859.	1.5	21
476	Glypican-3-targeted precision diagnosis of hepatocellular carcinoma on clinical sections with a supramolecular 2D imaging probe. Theranostics, 2018, 8, 3268-3274.	10.0	35
477	Novel GPC3-binding WS₂-Ga³⁺-PEG-peptide nanosheets for in vivo bimodal imaging-guided photothermal therapy. Nanomedicine, 2018, 13, 1681-1693.	3.3	17
478	Transgenic expression of the RNA binding protein IMP2 stabilizes miRNA targets in murine microsteatosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3099-3108.	3.8	10
480	Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 536-554.	17.8	158

#	Article	IF	Citations
481	Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma. Medicine (United States), 2018, 97, e11130.	1.0	49
482	Study on Diagnostic Values of Astrocyte Elevated Gene 1 (AEG-1) and Glypican 3 (GPC-3) in Hepatocellular Carcinoma. American Journal of Clinical Pathology, 2019, 152, 647-655.	0.7	12
483	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986269.	3.2	75
484	Improving the Detection of Hepatocellular Carcinoma using serum AFP expression in combination with GPC3 and micro-RNA miR-122 expression. Open Life Sciences, 2019, 14, 53-61.	1.4	12
485	Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. BMC Cancer, 2019, 19, 1088.	2.6	28
486	Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal?. Journal of Clinical Medicine, 2019, 8, 1736.	2.4	28
487	Preparation of novel targeting nanobubbles conjugated with small interfering RNA for concurrent molecular imaging and gene therapy in vivo. FASEB Journal, 2019, 33, 14129-14136.	0.5	18
488	Current Status of Gene Therapy in Hepatocellular Carcinoma. Cancers, 2019, 11, 1265.	3.7	40
489	Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers, 2019, 11, 1339.	3.7	80
490	Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986912.	3.2	70
491	An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis. Biomaterials Science, 2019, 7, 159-167.	5.4	22
492	Glypican-3 and Hep Par-1 are Useful Biomarkers in the Cytologic Assessment of Ascites. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 65-69.	1.2	0
493	The Selection of a Hepatocyte Cell Line Susceptible to Plasmodium falciparum Sporozoite Invasion That Is Associated With Expression of Glypican-3. Frontiers in Microbiology, 2019, 10, 127.	3.5	13
494	Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study. Molecular Biology Reports, 2019, 46, 2039-2047.	2.3	29
495	Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of Î²-catenin expression in lung squamous cell carcinoma. Bioscience Reports, 2019, 39, .	2.4	19
496	Mass spectrometry analysis of glycoprotein biomarkers in human blood of hepatocellular carcinoma. Expert Review of Proteomics, 2019, 16, 553-568.	3.0	5
497	Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Letters, 2019, 460, 1-9.	7.2	156
498	Reply. Gastroenterology, 2019, 156, 1933-1934.	1.3	0

#	Article	IF	Citations
499	rs2267531, a promoter SNP within glypican-3 gene in the X chromosome, is associated with hepatocellular carcinoma in Egyptians. Scientific Reports, 2019, 9, 6868.	3.3	13
500	Hepatocellular Carcinoma in Africa. , 2019, , 149-162.		0
501	Next-Generation Cancer Immunotherapy Targeting Glypican-3. Frontiers in Oncology, 2019, 9, 248.	2.8	86
502	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology, 2019, 12, 453-470.	3.1	28
503	A Systematic Investigation of the Malignant Functions and Diagnostic Potential of the Cancer Secretome. Cell Reports, 2019, 26, 2622-2635.e5.	6.4	57
504	Selective elimination of undifferentiated human pluripotent stem cells using pluripotent state-specific immunogenic antigen Glypican-3. Biochemical and Biophysical Research Communications, 2019, 511, 711-717.	2.1	11
505	Diffuse and canalicular patterns of glypicanâ€3 expression reflect malignancy of hepatocellular carcinoma. Pathology International, 2019, 69, 125-134.	1.3	5
506	Circulating Epithelial Cells in Patients With Liver Disease. Gastroenterology, 2019, 156, 1932.	1.3	0
507	Glypican-3 gene silencing for ovarian cancer using siRNA-PLGA hybrid micelles in a murine peritoneal dissemination model. Journal of Pharmacological Sciences, 2019, 139, 231-239.	2.5	17
508	Targeted and Multifunctional Technology for Identification between Hepatocellular Carcinoma and Liver Cirrhosis. ACS Applied Materials & Interfaces, 2019, 11, 14526-14537.	8.0	20
509	New Labyrinth Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in Hepatocellular Carcinoma. Scientific Reports, 2019, 9, 18575.	3.3	38
510	Identification of novel biomarkers for hepatocellular carcinoma using transcriptome analysis. Journal of Cellular Physiology, 2019, 234, 4851-4863.	4.1	38
511	Long non-coding RNA FENDRR inhibits proliferation and invasion of hepatocellular carcinoma by down-regulating glypican-3 expression. Biochemical and Biophysical Research Communications, 2019, 509, 143-147.	2.1	34
512	DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. OncoImmunology, 2019, 8, e1509173.	4.6	23
513	Glypicanâ€3â€Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Hepatology, 2019, 70, 563-576.	7.3	65
514	Heparan sulfate proteoglycan â€“ A common receptor for diverse cytokines. Cellular Signalling, 2019, 54, 115-121.	3.6	57
515	Developing slow-off dickkopf-1 aptamers for early-diagnosis of hepatocellular carcinoma. Talanta, 2019, 194, 422-429.	5.5	16
516	Proteoglycans remodeling in cancer: Underlying molecular mechanisms. Matrix Biology, 2019, 75-76, 220-259.	3.6	149

#	Article	IF	Citations
517	Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients. Journal of Gastrointestinal Cancer, 2019, 50, 434-441.	1.3	24
518	Primary Mediastinal Yolk Sac Tumors: An Immunohistochemical Analysis of 14 Cases. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 125-133.	1.2	12
519	CD24 as a Novel Predictive Biomarker in Patients with Hepatocellular Carcinoma: Friend or Foe?. Journal of Investigative Surgery, 2020, 33, 542-543.	1.3	1
520	Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression. Journal of Gastrointestinal Cancer, 2020, 51, 234-241.	1.3	20
521	Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma. Molecular Imaging and Biology, 2020, 22, 134-143.	2.6	14
522	Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update. Pediatric and Developmental Pathology, 2020, 23, 79-95.	1.0	114
523	Engineered Antiâ€GPC3 Immunotoxin, HN3â€ABDâ€T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. Hepatology, 2020, 71, 1696-1711.	7.3	42
524	Forkhead Box M1 Transcription Factor Drives Liver Inflammation Linking to Hepatocarcinogenesis in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 425-446.	4.5	12
525	Genomeâ€wide screening diagnostic biomarkers and the construction of prognostic model of hepatocellular carcinoma. Journal of Cellular Biochemistry, 2020, 121, 2582-2594.	2.6	10
526	Classification and Prognosis Prediction from Histopathological Images of Hepatocellular Carcinoma by a Fully Automated Pipeline Based on Machine Learning. Annals of Surgical Oncology, 2020, 27, 2359-2369.	1.5	33
527	Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma. Oncogene, 2020, 39, 1724-1738.	5.9	30
528	Functional glycomics: Application to medical science and hepatology. Hepatology Research, 2020, 50, 153-164.	3.4	17
529	Diagnostic accuracy of midkine for hepatocellular carcinoma: A metaâ€analysis. Molecular Genetics & Genomic Medicine, 2020, 8, e1071.	1.2	8
530	Integrin Î±6-Targeted Magnetic Resonance Imaging of Hepatocellular Carcinoma in Mice. Molecular Imaging and Biology, 2020, 22, 864-872.	2.6	8
531	Advances in the early diagnosis of hepatocellular carcinoma. Genes and Diseases, 2020, 7, 308-319.	3.4	189
532	Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians. Arab Journal of Gastroenterology, 2020, 21, 224-232.	0.9	3
533	32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma. Journal of Translational Medicine, 2020, 18, 295.	4.4	31
534	The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis. Frontiers in Cell and Developmental Biology, 2020, 8, 749.	3.7	49

#	Article	IF	Citations
535	Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma. Liver Research, 2020, 4, 168-172.	1.4	16
536	Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines, 2020, 8, 576.	3.2	37
537	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates, 2020, 51, 100702.	14.4	53
538	Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?. Journal of Clinical Medicine, 2020, 9, 1541.	2.4	38
539	MRIâ€Based Radiomics Signature: A Potential Biomarker for Identifying Glypican 3â€Positive Hepatocellular Carcinoma. Journal of Magnetic Resonance Imaging, 2020, 52, 1679-1687.	3.4	40
540	Progress and prospects of biomarkers inï¿½primary liver cancer (Review). International Journal of Oncology, 2020, 57, 54-66.	3.3	43
541	Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. Journal of Cancer, 2020, 11, 2008-2021.	2.5	79
542	Clinicopathological and prognostic significance of GPC3 in human breast cancer and its 3D structure prediction. Network Modeling Analysis in Health Informatics and Bioinformatics, 2020, 9, 1.	2.1	9
543	A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial. Cancer Immunology, Immunotherapy, 2020, 69, 1651-1662.	4.2	9
544	Recent advances in nanomaterial-enhanced biosensing methods for hepatocellular carcinoma diagnosis. TrAC - Trends in Analytical Chemistry, 2020, 130, 115965.	11.4	17
545	The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. Cancers, 2020, 12, 1734.	3.7	18
546	The Role of Glypicans in Cancer Progression and Therapy. Journal of Histochemistry and Cytochemistry, 2020, 68, 841-862.	2.5	42
547	Therapeutic Effect of Glypican-3 Gene Silencing Using siRNA for Ovarian Cancer in a Murine Peritoneal Dissemination Model. , 0, , .		0
548	Usefulness of Tumor Tissue Biopsy for Predicting the Biological Behavior of Hepatocellular Carcinoma. Anticancer Research, 2020, 40, 4105-4113.	1.1	10
549	Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. Biomolecules, 2020, 10, 934.	4.0	10
550	Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules, 2020, 25, 2861.	3.8	14
551	Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers, 2020, 12, 1668.	3.7	54
552	Circulating biomarkers for early detection of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093173.	3.2	26

#	Article	IF	Citations
553	Glypican-3 (GPC3) inhibits metastasis development promoting dormancy in breast cancer cells by p38 MAPK pathway activation. European Journal of Cell Biology, 2020, 99, 151096.	3.6	19
554	Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 827-840.	2.0	19
555	MetaOmGraph: a workbench for interactive exploratory data analysis of large expression datasets. Nucleic Acids Research, 2020, 48, e23-e23.	14.5	19
556	Adoptive T-cell therapy for HBV-associated HCC and HBV infection. Antiviral Research, 2020, 176, 104748.	4.1	31
557	Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer. Clinical Biochemistry, 2020, 79, 54-60.	1.9	37
558	Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology, 2020, 158, 2250-2265.e20.	1.3	97
559	Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Current HIV/AIDS Reports, 2020, 17, 6-17.	3.1	7
560	Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP. Journal of Clinical Medicine, 2020, 9, 323.	2.4	3
561	Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. Vaccines, 2020, 8, 41.	4.4	7
562	High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy. Human Pathology, 2020, 98, 56-63.	2.0	7
563	Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate. , 2020, 8, e000548.		13
564	Biomarkers for the Early Detection of Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2495-2503.	2.5	67
565	Targeting Tumorâ€Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. Hepatology, 2021, 73, 821-832.	7.3	25
566	Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis. Nephrology Dialysis Transplantation, 2021, 36, 1097-1103.	0.7	4
567	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. Critical Reviews in Oncology/Hematology, 2021, 157, 103167.	4.4	30
568	First evaluation of Neighbor of Punc E11 (NOPE) as a novel marker in human hepatocellular carcinoma. Cancer Biomarkers, 2021, 30, 75-83.	1.7	3
569	Generation of fully human anti-GPC3 antibodies with high-affinity recognition of GPC3 positive tumors. Investigational New Drugs, 2021, 39, 615-626.	2.6	3
570	Novel aptasensor-based assay of sonic hedgehog ligand for detection of portal vein invasion of hepatocellular carcinoma. Biosensors and Bioelectronics, 2021, 174, 112738.	10.1	10

#	Article	IF	Citations
571	A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 171-171.	1.7	19
572	Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. Cancer Gene Therapy, 2021, 28, 1075-1087.	4.6	23
573	Liver Diseases. , 2021, , 463-492.		1
574	Le Carbone prevents liver damage in non-alcoholic steatohepatitis-hepatocellular carcinoma mouse model via AMPKÎ±-SIRT1 signaling pathway activation. Heliyon, 2021, 7, e05888.	3.2	2
575	Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Frontiers in Oncology, 2020, 10, 605057.	2.8	4
576	AI-Based Radiological Imaging for HCC: Current Status and Future of Ultrasound. Diagnostics, 2021, 11, 292.	2.6	11
577	Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines, 2021, 9, 159.	3.2	20
579	RESULTS OF IMMUNOHISTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF EARLY HEPATOCELLULAR CARCINOMA AND NODULES WITH HIGH-GRADE DYSPLASIA IN PATIENTS WITH CIRRHOSIS. Arquivos De Gastroenterologia, 2021, 58, 82-86.	0.8	4
580	Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Frontiers in Immunology, 2021, 12, 655697.	4.8	126
581	The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma. Journal of Nanobiotechnology, 2021, 19, 74.	9.1	13
582	Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 653846.	2.8	2
583	Chimeric antigen receptor T cell therapy in oncology â€“ Pipeline at a glance: Analysis of the ClinicalTrials.gov database. Critical Reviews in Oncology/Hematology, 2021, 159, 103239.	4.4	21
584	Identification of nanobodies against hepatocellular carcinoma marker glypican-3. Molecular Immunology, 2021, 131, 13-22.	2.2	8
585	Development of Molecules Antagonizing Heparan Sulfate Proteoglycans. Seminars in Thrombosis and Hemostasis, 2021, 47, 316-332.	2.7	2
586	Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. , 2021, 9, e001875.		34
587	Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinomaÂin adults with chronic liver disease. The Cochrane Library, 2021, 2021, CD013346.	2.8	24
589	Design and Optimization of Orally Administered Luteolin Nanoethosomes to Enhance Its Anti-Tumor Activity against Hepatocellular Carcinoma. Pharmaceutics, 2021, 13, 648.	4.5	30
590	Identification METTL18 as a Potential Prognosis Biomarker and Associated With Immune Infiltrates in Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 665192.	2.8	11

#	Article	IF	Citations
591	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Medicina ClÃnica (English Edition), 2021, 156, 463.e1-463.e30.	0.2	16
592	Magnetic resonance imaging and diffusion-weighted imaging-based histogram analyses in predicting glypican 3-positive hepatocellular carcinoma. European Journal of Radiology, 2021, 139, 109732.	2.6	14
593	Circulating Biomarkers for Early Diagnosis of Hepatocellular Carcinoma. , 0, , .		1
594	Generation of dual functional nanobody-nanoluciferase fusion and its potential in bioluminescence enzyme immunoassay for trace glypican-3 in serum. Sensors and Actuators B: Chemical, 2021, 336, 129717.	7.8	24
595	Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. International Journal of Molecular Sciences, 2021, 22, 6139.	4.1	18
596	Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 4687-4696.	3.3	6
597	Screening of MicroRNA Related to Irradiation Response and the Regulation Mechanism of miRNA-96-5p in Rectal Cancer Cells. Frontiers in Oncology, 2021, 11, 699475.	2.8	3
598	State-of-the-art Hepatocellular Carcinoma Biomarker Detection by Biosensor Technologyâ€"a Review. Journal of Gastrointestinal Cancer, 2021, 52, 1081-1085.	1.3	1
599	Non-Coding RNA-Based Biosensors for Early Detection of Liver Cancer. Biomedicines, 2021, 9, 964.	3.2	12
600	Multi-Modal Imaging Probe for Glypican-3 Overexpressed in Orthotopic Hepatocellular Carcinoma. Journal of Medicinal Chemistry, 2021, 64, 15639-15650.	6.4	1
601	Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatology Communications, 2021, 5, 1972-1986.	4.3	24
602	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
603	Antitumor and Antioxidant Activity of S-Methyl Methionine Sulfonium Chloride against Liver Cancer Induced in Wistar Albino Rats by Diethyl Nitrosamine and Carbon Tertrachloride. International Journal of Environmental Research and Public Health, 2021, 18, 9726.	2.6	5
604	Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. Journal of Bone Oncology, 2021, 30, 100391.	2.4	8
605	Biosensor-based early diagnosis of hepatic cancer. , 2022, , 97-111.		0
606	Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells. Scientific Reports, 2021, 11, 40.	3.3	23
607	A multifunctional targeted nanoprobe with high NIR-II PAI/MRI performance for precise theranostics of orthotopic early-stage hepatocellular carcinoma. Journal of Materials Chemistry B, 2021, 9, 8779-8792.	5.8	15
609	Emerging Serum Biomarkers of HCC. , 2012, , 247-262.		2

#	Article	IF	Citations
610	Oncofetal Molecules as Biomarkers and Drug Targets for Hepatic Cancer. , 2013, , 57-74.		1
611	Pathology of Pediatric Liver Tumors. Pediatric Oncology, 2011, , 83-112.	0.5	9
612	Heparan Sulfate Proteoglycans in Infection. , 2011, , 31-62.		13
613	Laboratory Tests in Liver Diseases. , 2019, , 19-34.		1
615	Tumors and Cysts of the Liver. , 2010, , 1569-1592.e6.		3
616	Advanced Diagnostic Techniques. , 2010, , 395-437.		5
619	Radiomics, Radiogenomics, and Next-Generation Molecular Imaging to Augment Diagnosis of Hepatocellular Carcinoma. Cancer Journal (Sudbury, Mass), 2020, 26, 108-115.	2.0	12
622	Plasma and tumoral glypicanâ€3 levels are correlated in patients with hepatitis C virusâ€related hepatocellular carcinoma. Cancer Science, 2020, 111, 334-342.	3.9	13
623	Peptide vaccine as an adjuvant therapy for glypicanâ€3â€positive hepatocellular carcinoma induces peptideâ€specific CTLs and improves long prognosis. Cancer Science, 2020, 111, 2747-2759.	3.9	19
624	Complement factor Hâ€“deficient mice develop spontaneous hepatic tumors. Journal of Clinical Investigation, 2020, 130, 4039-4054.	8.2	30
625	Influence of Glypican-3 as Anewly Diagnostic Biomarker in Earlydetection of Hepatocellular Carcinoma among Saudi Patients. Biomedical and Pharmacology Journal, 2018, 11, 1789-1796.	0.5	3
626	Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histology and Histopathology, 2008, 23, 1333-40.	0.7	90
627	Tumor Markers and Hepatocellular Carcinoma. Journal of Biology and Today's World, 2015, 4, .	0.1	1
628	Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells. Oncotarget, 2016, 7, 60133-60154.	1.8	38
629	Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget, 2016, 7, 69916-69926.	1.8	37
630	Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. Oncotarget, 2017, 8, 37835-37844.	1.8	23
631	Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager. Oncotarget, 2017, 8, 52866-52876.	1.8	38
632	Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma. Oncotarget, 2015, 6, 43770-43778.	1.8	79

#	Article	IF	Citations
633	Glypican-3 and Alphafetoprotein as Diagnostic Tests for Hepatocellular Carcinoma. Molecular Diagnosis and Therapy, 2004, 8, 207-212.	1.1	13
634	Down-regulating Glypican-3 Expression: Molecular-targeted Therapy for Hepatocellular Carcinoma. Mini-Reviews in Medicinal Chemistry, 2015, 14, 1183-1193.	2.4	8
635	Recent Advances in Gene Therapy of Endometriosis. Recent Patents on DNA & Gene Sequences, 2014, 7, 169-178.	0.7	23
636	Expression of Glypican-3 (GPC3) in Malignant and Non-malignant Human Breast Tissues. The Open Cancer Journal, 2015, 8, 12-23.	0.2	7
637	Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnologica, 2019, 31, .	1.2	24
638	Glypican-3 Expression in Patients with Oral Squamous Cell Carcinoma. Journal of Dentistry, 2020, 21, 141-146.	0.1	5
639	Tumor Markers and Molecular Biology. , 2009, , 62-81.		1
640	Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Disease Markers, 2011, 31, 181-90.	1.3	51
641	Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis. Clinical and Molecular Hepatology, 2016, 22, 359-365.	8.9	23
643	Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. Cancers, 2020, 12, 3870.	3.7	13
644	Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma. Molecules, 2021, 26, 4.	3.8	19
645	Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis. World Journal of Gastroenterology, 2006, 12, 6473.	3.3	44
646	Serum tumor markers for detection of hepatocellular carcinoma. World Journal of Gastroenterology, 2006, 12, 1175.	3.3	294
647	Intratumoral sampling variability in hepatocellular carcinoma: A case report. World Journal of Gastroenterology, 2007, 13, 4019.	3.3	17
648	Present and future possibilities for early diagnosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2010, 16, 418.	3.3	161
649	Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World Journal of Gastroenterology, 2012, 18, 2408.	3.3	45
650	Increased expression of chondroitin sulphate proteoglycans in rat hepatocellular carcinoma tissues. World Journal of Gastroenterology, 2012, 18, 3962.	3.3	45
651	Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry. World Journal of Gastroenterology, 2014, 20, 5826.	3.3	50

#	Article	IF	Citations
652	Proteoglycans in liver cancer. World Journal of Gastroenterology, 2016, 22, 379.	3.3	82
653	Usefulness of plasma fullâ€'length glypicanâ€'3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery. Oncology Letters, 2020, 19, 2657-2666.	1.8	9
654	Biomarkers for hepatocellular cancer. World Journal of Hepatology, 2020, 12, 558-573.	2.0	30
655	Biological features and biomarkers in hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 2020.	2.0	12
656	Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2. World Journal of Hepatology, 2017, 9, 368.	2.0	7
658	Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma. Gut and Liver, 2014, 8, 177-185.	2.9	40
659	Tissue proteomics for cancer biomarker development - Laser microdissection and 2D-DIGE -. BMB Reports, 2008, 41, 626-634.	2.4	25
660	Predictive role BLVRA mRNA expression in hepatocellular cancer. Annals of Hepatology, 2016, 15, 881-887.	1.5	6
661	Glypican-3 as a Useful Diagnostic Marker That Distinguishes Hepatocellular Carcinoma From Benign Hepatocellular Mass Lesions. Archives of Pathology and Laboratory Medicine, 2008, 132, 1723-1728.	2.5	115
662	Update on Precursor and Early Lesions of Hepatocellular Carcinomas. Archives of Pathology and Laboratory Medicine, 2011, 135, 704-715.	2.5	129
663	Bicluster and Pathway Enrichment Analysis of HCV-induced Cirrhosis and Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2012, 13, 3741-3745.	1.2	17
664	Expression of Glypican-3 in Mouse Embryo Stem Cells and its Derived Hepatic Lineage Cells Treated with Diethylnitrosamine in vitro. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6341-6345.	1.2	8
665	Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4769-4775.	1.2	21
666	Current Trends and Recent Advances in Diagnosis, Therapy, and Prevention of Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3595-3604.	1.2	77
667	Sensitivity and Specificity of Galectin-3 and Glypican-3 in Follicular-Patterned and Other Thyroid Neoplasms. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, EC06-10.	0.8	9
668	Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers, 2021, 13, 5180.	3.7	9
669	In vitro 3D liver tumor microenvironment models for immune cell therapy optimization. APL Bioengineering, 2021, 5, 041502.	6.2	2
672	Genomic Profiling of Human Hepatocellular Carcinoma. , 2009, , 131-182.		0

#	Article	IF	Citations
673	Screening and Biomarkers for Hepatocellular Carcinoma. , 2009, , 327-348.		0
674	Approach to Solid Liver Masses in the Cirrhotic Patient. Gastroenterology Research, 2009, 2, 259-267.	1.3	1
675	Proteoglycans and Cancer. , 2010, , 191-215.		2
676	Chirurgische Therapie primÃrer maligner Lebertumoren. , 2010, , 595-637.		0
677	Histopathologie, Tumorklassifikationen und Prognosefaktoren. , 2010, , 88-105.		0
678	Malignant Tumors. , 2010, , 1305-1350.		0
679	Glypican-3-Expressing Hepatocellular Carcinoma in a Non-Cirrhotic Patient with Nonalcoholic Steatohepatitis: Case Report and Literature Review. Gastroenterology Research, 2010, 3, 223-228.	1.3	2
681	Application of anti-GPC3 monoclonal antibody in examination of hepatocellular tumors. Academic Journal of Second Military Medical University, 2010, 30, 711-714.	0.0	0
682	Fibrolamellar Hepatocellular Carcinoma. Molecular Pathology Library, 2011, , 849-857.	0.1	0
684	Chronic HCV and Hepatocellular Carcinoma. , 2012, , 47-60.		0
686	The Histomorphological and Immunohistochemical Diagnosis of Hepatocellular Carcinoma. , 0, , .		0
687	Re-Anchored GPC3-hAFP542-550 Fusion Protein Localizes to Hepatocellular Carcinoma Cell Membrane and Induces Cytokine Secretion by Lymphocytes. Immuno-gastroenterology, 2013, 2, 177.	0.4	0
688	Identification Of Hepatocellular Carcinoma Using Supervised Learning Algorithms. International Journal of Computers & Technology, 2015, 14, 5535-5542.	0.2	0
689	Diagnostic Immunopathology of Germ Cell Tumors. , 2017, , 131-179.		1
690	Role of Serum Glypican-3 in the Diagnosis of Hepatocellular Carcinoma in the Upper Egypt. Open Journal of Gastroenterology, 2018, 08, 415-423.	0.1	0
691	Preparation of a monoclonal antibody against the carcinoembryonic antigen, glypicanâ€‘3. Molecular Medicine Reports, 2019, 19, 3889-3895.	2.4	0
692	Roles of Tumor Markers in Diagnosis and Treatment of Hepatocellular Carcinoma. Korean Journal of Medicine, 2020, 95, 31-35.	0.3	0
693	Expression of NOTCH receptors and ligands and prognosis of hepatocellular carcinoma. Biomarkers in Medicine, 2020, 14, 1631-1639.	1.4	1

#	Article	IF	Citations
694	Radiolabeled Peptide Probes for Liver Cancer Imaging. Current Medicinal Chemistry, 2020, 27, 6968-6986.	2.4	8
695	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi Journal of Gastroenterology, 2020, 26, 1.	1.1	13
696	Clinical Features and Diagnostic Evaluation of Hepatocellular Carcinoma. , 2005, , 59-75.		1
697	Recent developments in the first detection of hepatocellular carcinoma. Clinical Biochemist Reviews, 2005, 26, 65-79.	3.3	39
698	Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles. Molecular Imaging, 2011, 10, 69-77.	1.4	27
699	Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepatitis Monthly, 2011, 11, 195-9.	0.2	25
700	Hepatocellular recurrence after orthotopic liver transplantation: Is combination of Î±-fetoprotein and glypican-3 a reliable marker?: Hepatocellular recurrence after orthotopic liver trasplantation. Hepatitis Monthly, 2011, 11, 155-6.	0.2	4
701	The role of glypican-3 in regulating Wnt in hepatocellular carcinomas. , 2011, 1, 14-19.		31
703	Anti-GPC3 single-chain scFv antibody acts as an agent for radio-immunoimaging in diagnosing hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2019, 11, 7422-7431.	0.0	2
704	Prognostic Influence of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis of Observational Studies. Frontiers in Surgery, 2021, 8, 769233.	1.4	4
705	Evaluation and impact of different biomarkers for early detection of hepatocellular carcinoma. Hepatoma Research, 0, 2020, .	1.5	0
706	NIR-II imaging of hepatocellular carcinoma based on a humanized anti-GPC3 antibody. RSC Medicinal Chemistry, 2022, 13, 90-97.	3.9	8
708	Recent advances in systemic therapy for hepatocellular carcinoma. Biomarker Research, 2022, 10, 3.	6.8	94
710	Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers, 2022, 14, 504.	3.7	14
711	Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy. Frontiers in Oncology, 2022, 12, 822449.	2.8	12
712	An Approach to the Simultaneous Detection of Multiple Biomarkers for the Early Diagnosis of Liver Cancer Using Quantum Dot Nanoprobes. Infectious Microbes & Diseases, 2022, 4, 34-40.	1.3	7
713	Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances. Advances in Cancer Research, 2022, , .	5.0	2
714	Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 824208.	2.8	28

#	Article	IF	Citations
715	GPAA1 promotes the proliferation, invasion and migration of hepatocellular carcinoma cells by binding to RNAâ€‘binding protein SF3B4. Oncology Letters, 2022, 23, 160.	1.8	1
716	Coreceptor functions of cell surface heparan sulfate proteoglycans. American Journal of Physiology - Cell Physiology, 2022, 322, C896-C912.	4.6	20
717	Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model. Pharmaceutics, 2022, 14, 815.	4.5	3
718	Evaluation of plasma LC3B+extracellular vesicles as a potential novel diagnostic marker for hepatocellular carcinoma. International Immunopharmacology, 2022, 108, 108760.	3.8	7
719	Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1579-1596.	3.7	8
720	Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma. Cancers, 2022, 14, 1902.	3.7	11
721	Production and characterization of GPC3-N protein and its nanobody. Protein Expression and Purification, 2022, 195-196, 106094.	1.3	0
722	Glypican-3. , 0, , 247-248.		0
732	Management of Hepatocellular Cancer. , 0, , 740-754.		0
734	Theranostic and precision medicine for the diagnosis of hepatocellular carcinoma. , 2022, , 275-286.		0
735	Expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma. Liver Research, 2022, 6, 66-71.	1.4	2
736	Radiomics on Gadoxetate Disodium-enhanced MRI: Non-invasively Identifying Glypican 3-Positive Hepatocellular Carcinoma and Postoperative Recurrence. Academic Radiology, 2023, 30, 49-63.	2.5	7
737	Targeted Molecular Imaging Probes Based on Magnetic Resonance Imaging for Hepatocellular Carcinoma Diagnosis and Treatment. Biosensors, 2022, 12, 342.	4.7	7
738	Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-Î¹B pathways and LncRNA-AF085935/GPC3 axis. Life Sciences, 2022, 303, 120675.	4.3	42
739	Nanocarrier-Based Tumor-Targeting Drug Delivery Systems for Hepatocellular Carcinoma Treatments: Enhanced Therapeutic Efficacy and Reduced Drug Toxicity. Journal of Biomedical Nanotechnology, 2022, 18, 660-676.	1.1	18
740	Proteoglycans. , 2022, , .		0
741	Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?. Liver Cancer, 2022, 11, 540-557.	7.7	6
743	Frequently expressed glypicanâ€3 as a promising novel therapeutic target for osteosarcomas. Cancer Science, 0, , .	3.9	2

#	Article	IF	Citations
744	An update on diagnostic tissue-based biomarkers in testicular tumors. Human Pathology, 2023, 133, 32-55.	2.0	9
745	Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging. Frontiers in Immunology, 0, 13, .	4.8	9
746	Multi-omics analysis revealed the role of extracellular vesicles in hepatobiliary & pancreatic tumor. Journal of Controlled Release, 2022, 350, 11-25.	9.9	3
747	Glypican-3 as a Serum Marker for Hepatocellular Carcinoma. Cancer Research, 2005, 65, 372-373.	0.9	159
748	Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. International Journal of Molecular Sciences, 2022, 23, 10038.	4.1	4
749	Prognostic value and morphological findings of overexpression of glypican-3 in hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 0, Publish Ahead of Print, .	1.6	1
750	The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2022, 23, 10279.	4.1	3
751	Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8+ T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma. Cancers, 2022, 14, 4512.	3.7	3
752	Possibility of Liver Cancer Treatment By Nanoformulation of Phenolic Phytochemicals. Current Nanomedicine, 2022, 12, 108-125.	0.6	1
753	Tumor buster - where will the CAR-T cell therapy â€˜missileâ€™ go?. Molecular Cancer, 2022, 21, .	19.2	23
754	Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma. Minerva Gastroenterology, 2022, 68, .	0.5	3
755	Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma. , 2022, , .		0
757	Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling. Theranostics, 2022, 12, 7903-7919.	10.0	4
758	The role of circadian gene timeless in gastrointestinal cancers. Gene Reports, 2023, 30, 101722.	0.8	0
759	Protein Glycosylation as Biomarkers in Gynecologic Cancers. Diagnostics, 2022, 12, 3177.	2.6	1
760	Soluble programmed death ligandâ€1â€induced immunosuppressive effects on chimeric antigen receptorâ€natural killer cells targeting Glypicanâ€3 in hepatocellular carcinoma. Immunology, 2023, 169, 204-218.	4.4	4
761	An electrochemical immunosensor for the detection of Glypican-3 based on enzymatic ferrocene-tyramine deposition reaction. Biosensors and Bioelectronics, 2023, 225, 115081.	10.1	5
762	Nanomedicines for hepatocellular carcinoma therapy: Challenges and clinical applications. Materials Today Communications, 2023, 34, 105242.	1.9	5

#	Article	IF	Citations
763	Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1369-1383.	3.7	1
764	Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC. Hepatology Communications, 2023, 7, e0022-e0022.	4.3	3
765	Clinical significance of cylindromatosis expression in primary hepatocellular carcinoma. Arab Journal of Gastroenterology, 2023, , .	0.9	0
766	Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection. Nature Communications, 2023, 14, .	12.8	6
767	Application of biological big data and radiomics in hepatocellular carcinoma. , 2023, 2, 41-49.		0
768	HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma. IScience, 2023, 26, 106143.	4.1	1
769	Elucidation of the Usefulness of Glypican-3, a Hepatocellular Carcinoma Biomarker, with the Fully Automated LUMIPULSE^{Â®} System. BPB Reports, 2023, 6, 21-26.	0.3	1
770	Immunotherapy for advanced or recurrent hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 405-424.	2.0	0
771	Precision diagnosis of hepatocellular carcinoma. Chinese Medical Journal, 2023, 136, 1155-1165.	2.3	4
772	Protective effects of butylated hydroxytoluene on the initiation of N-nitrosodiethylamine-induced hepatocellular carcinoma in albino rats. Human and Experimental Toxicology, 2023, 42, 096032712311656.	2.2	2
773	Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3. Cells, 2023, 12, 996.	4.1	4
774	A Statistical Approach to the Diagnosis and Prediction of HCC Using CK19 and Glypican 3 Biomarkers. Diagnostics, 2023, 13, 1253.	2.6	1
775	A wide scan of plasma proteins demonstrates thioredoxin reductase 1 as a potential new diagnostic biomarker for hepatocellular carcinoma. Scandinavian Journal of Gastroenterology, 2023, 58, 998-1008.	1.5	3
776	Structural and Functional Impact of Posttranslational Modification of Glypican-3 on Liver Carcinogenesis. Cancer Research, 2023, 83, 1933-1940.	0.9	6
777	A cell transmembrane peptide chimeric M(27â€“39)-HTPP targeted therapy for hepatocellular carcinoma. IScience, 2023, 26, 106766.	4.1	0
778	Targeted Therapy and Personalized Medicine. Cancer Treatment and Research, 2023, , 177-205.	0.5	2
779	Targeting transglutaminase 2 mediated exostosin glycosyltransferase 1 signaling in liver cancer stem cells with acyclic retinoid. Cell Death and Disease, 2023, 14, .	6.3	2
780	Glypicans, 35 years later. , 2023, 1, .		3

#	Article	IF	Citations
781	Circulating biomarkers for diagnosis and management of hepatocellular carcinoma. World Chinese Journal of Digestology, 2023, 31, 404-411.	0.1	0
782	Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients. International Journal of Molecular Sciences, 2023, 24, 10922.	4.1	1
783	NAFLD and NAFLD-related HCC in Asia: Burden and Surveillance. Journal of Clinical and Experimental Hepatology, 2024, 14, 101213.	0.9	2
784	Advances in adoptive T-cell therapy for metastatic melanoma. Current Research in Translational Medicine, 2023, 71, 103404.	1.8	3
785	Delta-radiomics models based on multi-phase contrast-enhanced magnetic resonance imaging can preoperatively predict glypican-3-positive hepatocellular carcinoma. Frontiers in Physiology, 0, 14, .	2.8	1
786	The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability. Cell Reports Medicine, 2023, 4, 101170.	6.5	1
787	Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population. BMC Gastroenterology, 2023, 23, .	2.0	0
788	Identification and validation of microtubule depolymerizing agent, CYT997, as a potential drug candidate for hepatocellular carcinoma. Liver International, 2023, 43, 2794-2807.	3.9	0
789	Liquid biopsy for early detection of hepatocellular carcinoma. Frontiers in Medicine, 0, 10, .	2.6	1
790	Global impact of proteoglycan science on human diseases. IScience, 2023, 26, 108095.	4.1	1
791	Multiparametric MRI combined with clinical factors to predict glypican-3 expression of hepatocellular carcinoma. Frontiers in Oncology, 0, 13, .	2.8	0
792	Molecular profiling in the management of hepatocellular carcinoma. Current Opinion in Organ Transplantation, 2024, 29, 10-22.	1.6	1
793	Current methods for the detection of glypican-3. Analytical Methods, 2024, 16, 152-160.	2.7	0
794	Evaluation of serum thioredoxin as a hepatocellular carcinoma diagnostic marker. Egyptian Liver Journal, 2024, 14, .	0.6	0
795	Cellular Changes Resulting from Forced Expression of Glypican-3 in Hepatocellular Carcinoma Cells. Molecules and Cells, 2006, 21, 224-228.	2.6	0
796	Biomarker in Hepatocellular Carcinoma. Indian Journal of Surgical Oncology, 0, , .	0.7	0
797	Engineered exosomes loaded with M1â€“8 peptide for targeted therapy of hepatocellular carcinoma. Applied Materials Today, 2024, 37, 102071.	4.3	0
798	Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?. International Journal of Molecular Sciences, 2024, 25, 2631.	4.1	0

#	Article	IF	Citations
799	Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2024, 65, 586-592.	5.0	0
800	20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3â€mediated Wnt/βâ€‘catenin signaling pathway. Acta Biochimica Et Biophysica Sinica, 2024, , .	2.0	0